Sign inJoin free

Watch / CEOs & MDs

Recce leads new antibiotic class, first in 40+ years

12 Mar 20248:11

Recce leads new antibiotic class, first in 40+ years

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

James Graham, CEO of Recce Pharmaceuticals (RCE), underlines the company's progress in the clinical trial of their emerging anti-infection treatment, RECCE 327. The treatment is aimed at combating severe infections, such as urinary tract infections and sepsis. James reveals a boost to the company's cash position, following an $11 million R&D rebate and a raise of roughly $12 million between institutions and existing shareholders. Notably, Fidelity took a 7.7% ownership stake in Recce.

James also highlights Recce's recent breakthrough in Indonesia, exploiting the high prevalence of diabetes and related infections in the country. With over 10% of the population having diabetes, and a higher likelihood of infection among them, Recce's treatment presents an enormous opportunity. James expresses Recce's commitment to tackle the infectious disease crisis, from the underlying diabetic foot infection to other diabetes co-morbidities such as UTIs or septic infections.

A significant part of the conversation focuses on the properties of their synthetic anti-infective and the timescales for entering the market. James explains that recce 327 has been designed to work reliably and repeatedly. Looking at around 18 to 24 months to obtain regulatory approval via the primary focus pathway with the FDA or potentially an even quicker path to revenue under the Indonesian pathway. Lastly, James emphasises the need for their product given the increasing antibiotic resistance and the desire for effective treatments.

Find the full unedited transcript of this interview below:

Now Recce Pharmaceuticals, because kicked off a new phase in its clinical trial testing a promising anti infection treatment called recce 327. This trial could lead to a breakthrough treatment for severe infections like UTIs and sepsis, which impact millions worldwide. So to get across the details, Recce 's CEO James Graham joins me up on the desk. You guys have been very busy of late. I see there's quite a lot that's been happening. We certainly have. And it's great to be with you. Yeah, fantastic. Thank you so much for coming in. So before we actually get to this announcement, there's a few other things that have been happening. And I did a little bit of research because you spoke with us in about, I think, September, October last year just after you done an issue. That's right. Exactly. Yeah. Fidelity took 7.7% ownership of our company. And most of the in fact, all the directors participated in the raise and we raised around or I've got to remember my stats, about $12 million between institutions and existing

0:59

shareholders. Okay. And I was just noting here, the last Friday you announced $11 million R&D rebate to also just improve your cash positions. Look, absolutely. One is dilution affecting the capital structure, which of course was the one completed in October, which put us in an excellent position. This is non-discretionary a non dilution free cash injection to the company. In fact it's entirely unprecedented in a few fold. One is it's capturing our R&D rebate of the last financial year. But two it's actually forward facing. So it's capturing expenditure we anticipate incurring. But receiving the cash benefit here today without any consequence to our intellectual property or similar. So I really see it as a fantastic padding or foundation supporting our cash position to get ahead with these clinical studies. Absolutely. And you've also announced a major deal in Indonesian recently. Can you run us through that one? That was

1:59

that is extraordinary. The opportunity in Indonesia, we have or they have 278 million persons worldwide each year. Over 10% of the population has diabetes. And if you have diabetes, a few things happen one, you're twice as likely to get an infection. Two about 35% of those with diabetes get a diabetic foot ulcer, which becomes infected. The A therapy for that is most commonly amputation. And three if you do have a surgery, any type of surgery, you're extremely likely likely to get infected. And of course, for a urinary tract, infections are prevalent, so we look to support or own. If I think capitalistic that infectious disease crisis from the underlying diabetic foot infection through to the all out morbidities or co-morbidities that occur with diabetes, a urinary tract infection. So 30% of septic infections, which is the largest, most expensive condition treated to date. So Indonesia's been a

2:59

real rather than us pushing. It's they pulling to have access to new medicine. As World Health and Pew Charitable Trusts say, we are the most clinically advanced new class of antibiotic in the world at this time and the first in over 40 years. So it's a privileged position of being wow. So just want us through three, two, seven and these these tests that you're doing because um, you've got four infusion times. Just break it down simplistically what the results actually mean. Yeah. Look we we take a portfolio approach. So we jump between IV for being a straight into human vein which is focused upon neuro sepsis. So the underlying urinary tract infection I mentioned 30% of septic patients have through to the all out blood poisoned or bacteria ridden patient, which is sepsis or broad spectrum sepsis. That's one of our programs, the FDA's to my knowledge, we are the only qualified infectious disease candidate for that. According to the FDA. We've completed dosing diabetic foot infected patients out of

3:59

New South Wales, leading teaching hospital in Liverpool. All patients had a complete response. We take that topical method of administration, having a dose with Professor Fiona Ward and colleagues on burn wound patients out of Western Australia to now adopt that into Indonesia and across to the US, where we're very active with groups like the US Department of Defense. Um, it sounds absolutely amazing. Um, what sort of time frame before this new class of, um. It's interesting. It's a synthetic anti-infective. Is it? It's the very first. That's right. So we actually call it an antibiotic for simplicity and communication. All antibiotics are naturally derived bacterial fungi. You find them, you cultivate them out, you put them against the offending. It's kind of not inventive. We've began with first principles in mind. It's wholly synthetic, means it has designed properties, works with works, and keeps on working with repeated use, plus a synthetic method of manufacture rather than expensive time.

4:59

Assuming cultivation of all existing antibiotics. So beginning with the end in mind, putting against the challenge that is and we're getting success in doing that. What's the lead time before your product could potentially, you know, go into market from a portfolio perspective where we see a topical administration, which is the lower hanging fruit or the easier method of administration and less regulatory burden, if I suppose, just because it's not as invasive, you're really looking at twofold, one through the Australian and FDA, as is our primary focus pathway, which could be some 18 to 24 months to a to a to a revenue, and I think could be quite profitable from there or under the Indonesia pathway, which should be positioned as a registration or phase three study, initially in a topical form. Uh, we'll define what that looks like in the near term, which could be an even faster regulatory track and path to revenue there, too. But really, as each one drops in, you're looking

5:59

at unmet medical needs so not serviced by existing antibiotics of large patient populations, really Western patient populations where you have price monopolies. Mhm mhm. Absolutely fascinating. And in terms of um at what point if you were starting to see some adverse side effects in these tests, when would they start to throw up, to throw up or to show up? I think it's a little bit. Yeah. Sorry. Not literally. No, no. But show up. That would be considered an adverse events. Yeah. Well quite not a serious adverse event depending on what comes up. But look, you really, um, the goal frankly, from a, when it's a safety study you're looking for, for effects, uh, you increase the dose consistently, whether it be increase in concentration or narrow the time of, of administration to obviously have a natural reaction, reactionary period. You're trying to get a side effect. You're actually trying to break a sweat or to see a change in telemetry or change in organ function or change

6:59

changing. We haven't seen any. In fact, the only thing we've really seen, uh, in some cases is stinging around the infusion site. Look, if you've got sepsis, you're going to be an organ failure anyway. So a little bit of stinging is not of any consequence. Quite. What's the significance of your synthetic drug, um, versus the traditional drugs there. Is it because there's a lot of, um, antibiotic resistance emerging? Is that one of the key reasons why recce has been, you know, pursuing this? Yeah. Look, we we work and we keep on working with repeated use. I remember I remember the days you go to the doctor, say five, ten years ago, they'd say, take this antibiotic prescription for whatever your little infection may be and you'll get better. Now you go there with the same infection, whatever it may be. And they say, take this prescription and make sure you complete the follow on repeats. It's the same drug, the bacteria mutating, the antibiotics are no longer keeping up. And that in our eyes, is actually antibiotic resistance

7:58

occurring. So the faster you can get on top of a patient infection, the better the patient outcome, the reduction on the farmer economic burden that takes place through the healthcare system carrying this. And of course, who doesn't want a product that actually works?

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy